- The P-IIb/III SELECTION study involves assessing of filgotinib (200/ 100mg) vs PBO in 1,348 biologic-naïve & biologic-experienced patients in a ratio (2:2:1) with mod. to sev. UC. The SELECTION study consists of 2 induction trials and a maintenance trial
- Filgotinib (200mg) achieved all its 1EPs inducing clinical remission @10wks. in biologic-naïve & experienced patients (26.1 % vs 15.3% & 11.5% vs 4.2%) and maintaining clinical remission @58wks. (37.2% vs 11.2) while in 100mg arm, clinical remission @58wks. (23.8% vs 13.5%) and did not achieve clinical remission @10wks.
- Filgotinib is an investigational, oral, selective JAK1 inhibitor and is currently under US FDA, EMA and MHLW’s review the for the treatment of RA
Click here to read full press release/ article | Ref: Gilead | Image: PharmaForum